OraSure's Intercept Oral Fluid Drug Test Results Comparable to Urine Drug Screening According to Landmark Five-Year Analysis

  
    
  
  
    
      OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that findings 
      from a recent large-scale study of laboratory-based oral fluid drug 
      testing results are comparable to urine drug testing positive rates for 
      the same classes of drugs. The 650,000 oral fluid laboratory test 
      results analyzed, of which 98% were conducted with the Intercept® 
      oral fluid drug testing system, were collected over a five-year period 
      of time in the non-federally regulated workplace market.
    
    
      The results of this expansive study, which was sponsored by the U.S. 
      Department of Health and Human Services Substance Abuse and Mental 
      Health Services Administration (SAMHSA), were presented by Dr. J. 
      Michael Walsh on October 29, 2008 at the annual meeting of the Society 
      of Forensic Toxicologists (SOFT). A copy of the abstract can be found 
      later this week at the SOFT web site at www.soft-tox.org.
    
    
      “The results of this analysis clearly indicate 
      that oral fluid laboratory drug testing and in particular our Intercept® 
      drug test are producing comparable outcomes to urine-based testing,” 
      said Dr. Stephen Lee, OraSure’s Chief Science 
      Officer.
    
    
      Developed and manufactured by OraSure Technologies, the Intercept® 
      Drug Test is the only FDA-cleared in vitro diagnostic 
      laboratory-based oral fluid testing system used for detecting commonly 
      abused drugs such as marijuana, cocaine, opiates, PCP and amphetamines 
      (including methamphetamine and ecstasy) and for detecting barbiturates, 
      methadone and benzodiazepines. Intercept® 
      testing is currently being used in workplace, drug treatment and 
      criminal justice testing markets, as well as in public school systems.
    
    
      About OraSure Technologies
    
    
      OraSure Technologies develops, manufactures and markets oral fluid 
      specimen collection devices using proprietary oral fluid technologies, 
      diagnostic products including immunoassays and other in vitro 
      diagnostic tests, and other medical devices. These products are sold in 
      the United States as well as internationally to various clinical 
      laboratories, hospitals, clinics, community-based organizations and 
      other public health organizations, distributors, government agencies, 
      physicians’ offices, and commercial and 
      industrial entities.
    
    
      OraSure Technologies is the leading supplier of oral-fluid testing 
      solutions for drugs of abuse and for the detection of antibodies to HIV.
    
    
      For more information on the Company, please go to www.orasure.com.